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ABSTRACT 
Objective: The objective of the current study was to evaluate the quality control parameters of seven brands of levofloxacin 500 mg film-coated 
tablet available in the Yemeni market. 
Methods: Physicochemical parameters assay was performed for seven brands of levofloxacin 500 mg film-coated tablet. Each brand was subjected 
to official and unofficial in vitro quality control tests, including weight variation, thickness, hardness, friability, disintegration, dissolution, and 
content uniformity assay by High-Performance Liquid Chromatography (HPLC). 
Results: Out of seven, six brands of levofloxacin 500 mg film-coated tablet passed official specified assay tests according to the United States 
Pharmacopeia (USP) specifications. They showed a similar profile of thickness ranged between±0.01 and 0.10%, friability ranged between 0.01% 
and 0.34%, disintegration time ranged between 3.00 and 15.00 min, dissolution percentage ranged between 90.650 and 103.05 and content 
uniformity ranged between 93.62 and 107.12%. Regarding weight variation and hardness, six brands passed the weight variation test and only 
three brands showed optimum range (10-20 kg) of hardness test. Only one brand failed to pass the weight variation test, and four brands failed to 
pass the optimum range (10-20 kg) of hardness. 
Conclusion: There are no remarkable differences between the seven brands regarding in vitro quality control tests of content uniformity, thickness, 
friability, disintegration, and dissolution. Even though four brands were above the optimum range of hardiness, they showed complete disintegration 
and dissolution within the acceptable limit. Regular assessment of marketed drugs is required to ensure bioequivalent to their innovators. 
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INTRODUCTION 
One of the most prescribed drugs in modern medicine is antibiotics. 
They are widely used to treat bacterial infections by killing or 
inhibiting bacteria [1]. Levofloxacin is a synthetic fluoroquinolone 
agent; it has a broad spectrum to fight different kinds of bacteria in the 
body of Gram-positive and Gram-negative organisms for oral and 
intravenous administration. Chemically, it is the pure (-)-(S) 
enantiomer of the racemic drug substance Ofloxacin. Levofloxacin is 
widely used in the treatment of bacterial infections of the skin and 
urinary tract infections, as well as upper and lower respiratory tract 
infections, such as acute bacterial sinusitis, acute exacerbations of 
chronic bronchitis, and community-acquired pneumonia [1-3]. A film-
coated tablet has some advantages over other types, as it is covered 
with a coating to mask the unpleasant odor and taste, to allow the 
tablet to pass into the small intestine without disintegration in the 
stomach, and to enhance the stability and strength of the tablet [4].  
Biochemical and pharmacological quality control tests for different 
brands of pharmaceutical products that contain the same active 
ingredients are vital steps to confirm therapeutic equivalence for 
such products. Additionally, oral dosage forms depend profoundly 
on dissolution studies in vitro to predict their bioavailability in vivo 
[1, 5]. Furthermore, the official and unofficial quality control tests in 
vivo-in vitro are required to confirm the safety and efficacy of any 
pharmaceutical product [6]. 
In Yemen as well as other poor countries, the price of drugs is the 
main factor in determining patient's access to health care, where 
many people put off the use of needed medicines due to the high cost 
of branded products. Moreover, few studies have been conducted so 
far to evaluate drugs' quality control in Yemen [6-8]. Therefore, 
further studies should be conducted in this field to evaluate the 
quality control tests for locally and internationally manufactured 
drugs, to ensure the quality and efficacy of the pharmaceutical 
products, and to offer suitable substitutions to patients.  
Even though there are many different brands of levofloxacin available 
in the Yemeni market and the clinical use of levofloxacin is highly 
increased among the public, there is no quality control study has been 
conducted on this field in Yemen. The findings of this study can be 
used as a source of information to drug regulatory authorities and 
drug manufacturers in Yemen. Accordingly, this study was aimed to 
evaluate the quality control of different brands of levofloxacin 500 mg 
film-coated tablet available in the Yemeni market.  
MATERIALS AND METHODS  
Materials 
All materials were purchased from Scharlab S. L. (Scharlau Chemie s. a, 
Spain) and were supplied by Modern Pharma Pharmaceutical 
Industry. Trifluoracetic acid, Acetonitrile, Hydrochloric acid 0.1 N, and 
Ethanol absolute ≥ 99.8%. Distilled water was papered with (PH 7). 
Instruments 
HPLC (High-Performance Liquid Chromatography; Waters, model: 
Pump, 1525, Detector, 2998, Germany) and USP dissolution apparatus 
paddle method-type II (PHARMA TEST: PTWS 1220, Germany). Other 
instruments used included a Micrometer for thickness test (Mitutoyo 
operating manual, Japan), Tablet Hardness Tester (PHARMA TEST: 
PTB, 111E, Germany), a Friabilator (PHAMA TEST: PTB 10E, 
Germany), an Electronic balance (KERN and SOHN: ABS 220-4, 
Germany), and disintegration tester (PHARMA TEST: PTZ S, Germany).  
Methods 
Study design 
Official and unofficial quality control parameters, including weight 
variation, thickness, hardness, friability, disintegration time, 
dissolution profile and content uniformity assay, were studied in 
International Journal of Applied Pharmaceutics 
ISSN- 0975-7058                               Vol 13, Issue 2, 2021 
Battah et al. 
Int J App Pharm, Vol 13, Issue 2, 2021, 264-268 
 
265 
vitro for comparison between seven commercial brands of 
levofloxacin 500 mg film-coated tablet available in the Yemeni’s 
market.  
Samples collection  
Seven brands of levofloxacin 500 mg film-coated tablet were 
obtained from different retail pharmacies in Sana´a, Yemen. Study 
samples were collected from January 20th to February 20th
  
, 2020. All 
of the selected brands of levofloxacin were plain compressed 
uncoated tablets. The seven brands were checked for their strength, 
batch number, manufacturing and expiry dates, as well as they, were 
coded from A to G (table 1). All chemicals used were of Analytical 
Grade, and the standard procedures were used during all analytical 
processes. The study samples were stored at 25 °C according to the 
manufacturers' instructions before evaluation. 
Table 1: List of the tested commercial levofloxacin 500 mg film-coated tablet in Yemen 
Country Code Brands Strength Manufacturer Batch No. Mfg. Date Exp. Date 
Argentina A Leflumax 500 mg Elea S. A. C. I. F. 5466 07/2018 07/2021 
Egypt B Lee-flox 500 mg Pharo-Pharma 114 7005 05/2017 05/2020 
Yemen C Levota 500 mg RFA-Pharma 17A275B 12/2017 12/2020 
Yemen D Lefoxin 500 mg Modern Pharma 19138 02/2019 02/2022 
Yemen E Levomax 500 mg Y. E. Pharma 5466 02/2019 02/2022 
India F Levolab 500 mg Laborate pharmaceutical LLNT-002 06/2018 05/2021 
India G Levobact 500 mg Cipla ltd. BA80151 12/2017 11/2020 
 
Physiochemical parameters measurement 
Thickness test 
Thickness measuring test is necessary to facilitate packaging. To 
carry out this test, ten tablets from each brand were examined. The 
mean of each brand was determined in mm within an acceptable 
variation of±5% of the size of the tablet [9]. 
Hardness test 
The hardness of tablets is essential to withstand mechanical shocks 
during the different processes of manufacturing, handling, packaging 
and transporting. Ten tablets were selected from each brand and 
subjected to Tablet Hardness Tester. Hardness and mean hardness 
were calculated for each brand. The minimum adequate value of 
tablet hardness (crushing strength) is 4 kg or above, while the 
optimum hardness for coated tablets is 10-20 kg [10, 11]. 
Friability test 
Tablet friability is an essential factor for the tablet to withstand 
attrition in the package container because of chipping and 
powdering or fragmentation of the tablets during handling and 
shipping. It can adversely affect the tablet appearance, acceptance, 
weight variation and content uniformity [12]. Friability test 
evaluates the impact of transporting tablets from the 
manufacturer to the point of sale, as no sample is assumed to lose 
more than 1% of its weight after testing to withstand rough 
handling and transportation through potholed roads [13]. In order 
to carry out this process, twenty tablets of each levofloxacin 500 
mg brand were weighed initially and then subjected to abrasion 
using a Friabilator. The Friabilator was set to make 100 
revolutions in 4 min. Later on, the tablets were removed from the 
Friabilator and reweighed again after dusting. The friability was 
calculated by measuring the difference in weight according to the 
following equation [14]:  
Friability =
Weight before −  Weight after
Weight before
×  100  
The acceptable limit of friability is up to 1% [15].  
Weight variation test 
This test is used to ensure a constant dose of drugs between 
different brands. Twenty tablets were selected from each brand and 
weighed using an Electronic balance, then each tablet was weighed 
individually. The average of weight variations for all brands was 
calculated. 
The weight variation for an individual brand should not exceed±5% 
according to the United State Pharmacopeia (USP) and British 
Pharmacopeia (BP) standers; to pass, no more than 2/20 tablet 
differ by more than the percentage permitted and no one tablet 
differ by more than double the percentage [11, 16, 17].  
Disintegration 
To measure the time required for tablets to breakdown into small 
particles, the disintegration test was performed by disintegration 
tester in a medium of 0.1 N HCL and a temperature of 37±1 °C. A 
disintegration test is carried out using 6 coated tablets according to 
the USP. The required time for each tablet to disintegrate and pass 
out through the mesh was recorded, and the mean disintegration 
time for each brand was then calculated [18].  
Dissolution 
The pattern of levofloxacin released over a certain period of time can 
be determined by the dissolution test. As part of the In vitro-In vivo 
correlation, all dissolution test parameters should be set to be 
identical to the human body’s conditions [19]. Using the dissolution 
apparatus, the dissolution medium was prepared with 900 ml of 0.1 
N HCL, and the dissolution process was performed at a temperature 
of 37±0.5 °C and a speed of 75 rpm. Furthermore, an amount of 5 ml 
as samples were withdrawn every 10 min and replaced with an 
equal amount of fresh dissolution medium. The obtained samples 
were subjected to be suitably diluted and analyzed for levofloxacin 
using HPLC at 294 nm, where the absorbance was measured and the 
percentage of drug release was determined [14, 20]. 
Content uniformity assay 
The active ingredient uniformity test of the tablets was carried out 
using HPLC. Diluent and Trifluoroacetic acid were prepared freshly 
in a ratio of 1000 to 1 were used as the mobile phase; the diluent 
contains water and acetonitrile in a ratio of 82 to 18. The flow rate of 
the mobile phase was 0.7 ml/min, and the injection volume of the 
sample was 20 μl. Levofloxacin detection wavelength was set at 294 
nm. The acceptable limit for drug content, chemical compliance and 
content of active ingredients uniformity tests were carried out in 
accordance with the standard method specified in USP [17].  
Data analysis 
Tablets’ weight variation, content uniformity, hardness, friability, 
thickness, disintegration, and dissolution tests were analyzed by 
calculating the mean±standard deviation (SD) for each test using IBM 
SPSS Statistics version 21.0 for Windows (IBM Corp., Armonk, NY, USA).  
RESULTS  
Thickness, friability, and hardness of levofloxacin brands  
Thickness, friability, and hardness results among all brands are 
summarized in table 2. Among all brands, the average thickness of 
the seven brands was ranged between±0.01 and 0.10%. Out of 
seven, four brands failed to pass the optimum range of hardness. The 
friability test among all brands was ranged from 0.01% to 0.34%; 
the highest value was found with brand E. The maximum crushing 
strength was found in brand C (25.76 kg/cm²), while the lowest one 
was found in brand A (17.33 kg/cm²). 
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Table 2: Thickness, friability, and hardness for seven brands of levofloxacin 500 mg film-coated tablets 
Code Hardness (kg/cm²) (n = 10) Friability (w/w) (n = 20) Thickness (mm) (n = 10) 
A 17.33±0.6 0.01±0.02 5.3491±0.01 
B 25.34±1.7 0.29±0.01 5.5544±0.01 
C 25.76±4.92 0.01±0.04 5.8651±0.03 
D 18.50±1.0 0.01±0.04 5.2357±0.10 
E 21.72±1.0 0.34±0.02 5.4549±0.04 
F 19.98±3.32 0.09±0.06 5.5501±0.01 
G 21.97±1.0 0.01±0.06 5.2581±0.04 
Limits 10-20 kg/cm² <1% ±5% 
Data given in each reading as mean±SD (SD: Standard Deviation)  
 
Official quality control parameters results  
Weight variation, disintegration time, dissolution time, and content 
uniformity of levofloxacin brands results are summarized in table 3. 
Mean weight of the seven brands was ranged between 623.1±10.8 
for brand E and 968.8±27.7 for brand F, and the weight range for all 
seven brands was 69%-73% of the mean weight, whereas it was 70-
80% for brand C. Mean disintegration time for all brands was ranged 
between 3.00 to 15.00 min. The mean dissolution time percentage 
was ranged from 90.650 to 103.05, while the content uniformity for 
all brands was ranged from 93.62 for brand C to 107.12% for brand 
E. All brands were compliant with quality control parameters 
according to USP specification except weight variation, where one 
brand did not pass the weight variation test. 
 
Table 3: Official quality control parameters for seven brands of levofloxacin 500 mg film-coated tablets 
Code 
 
Weight variation Content uniformity 
(%) (n = 20) 
Disintegration time 
(min) (n = 6) 
Dissolution time % 
(after 30 min) (n = 6) (mg) (n = 20) (range % from mean) 
 A 623.4±2.4 62-63 100.48±0.450 11.00±0.018 100.71±3.22 
 B 650.7±5.1 64-66 99.51±0.267 6.00±0.026 90.650±1.72 
 C 755.3±25.5 70-80 93.62±0.663 15.00±0.087 99.640±0.65 
 D  723.2±5.8 71-73 99.91±0.461 3.00±0.025 100.49±2.70 
 E 623.1±10.8 61-64 107.12±0.141 8.00±0.076 100.62±1.19 
 F 968.8±27.7 92-102 105.01±0.070 12.00±0.028 103.05±0.53 
 G 657.0±4.0 64-66 105.03±0.649 7.00±0.021 100.86±1.51 
Limits  ±5 90–110 % 30 >80 % 
Data given in each reading as mean±SD (SD: Standard Deviation)  
 
DISCUSSION  
To the best of our knowledge, this study was conducted as the first 
one to evaluate official and unofficial quality control parameters of 
different brands of levofloxacin 500 mg film-coated tablets that were 
available on the Yemeni market. 
The uniformity in the thickness of tablets was pivotal for tablets’ 
packaging and consumers’ requirements [21]. Our findings showed 
that the variation of tablets’ thickness was within the accepted limit; 
±5%, where it was ranged between±0.01 and 0.10%. In agreement 
with our findings, a previous study revealed the closeness of all film-
coated tablets’ thickness, where the standard deviation was found 
between 0.02-0.06 [22]. 
According to USP, the satisfactory limit of friability is not greater 
than 1% [17]. Our findings of all levofloxacin brands were in 
agreement with the USP standers and fulfill this criterion to confirm 
the mechanical stability of all brands. Additionally, this finding was 
in agreement with previous studies conducted on different brands of 
levofloxacin 250 mg and ciprofloxacin 500 mg, where they revealed 
that tablets with the highest value of hardness showed a low 
friability value [2, 7]. 
Regarding weight variation, when the strength of the active 
ingredient is greater than 324 mg in a tablet, its weight variation 
fulfills the requirements if the mean weight of each brand does not 
deviate by more than±5% as recommended by USP [17]. The finding 
of the current study showed that out of seven, six brands (A, B, D, E, 
F and G) were passed the USP specifications, while brand C did not 
comply with the USP specifications. The most logical explanation for 
the discrepancy in the average weight between different products 
might be attributed to the differences in the excipients and 
technique during manufacturing. Additionally, the variations of 
weight might be attributed to the improper tooling sets and poor 
granulation flow properties during formulation. The variation in the 
tablet’s weight might cause variances in the tablet’s size that play an 
important role in the compliance of patients. A comparable study 
conducted in Pakistan showed remarkable variations in the 
weight of levofloxacin tablets 250 mg; however, such variations 
are meaningless as long as the tablet thickness is adjusted 
accordingly [1].  
Additionally, other previous studies revealed that weight variation 
of the tablet dosage form is also being indicative of the uniformity of 
drug contents, as any weight variation obviously reflects variation in 
the content of active pharmaceutical ingredients [23-25]. In our 
study, all the seven brands of levofloxacin, even brand C that did not 
pass the weight uniformity test, were displayed an acceptable range 
of drug contents as specified by USP; between 90% and 110% [17]. 
The slight differences in drug contents among levofloxacin brands 
may be attributed, in part, to the non-uniform weight of active 
ingredients or poor storage conditions during the manufacturing 
process and shipping. 
Tablet hardness depends on the weight of the used materials, the 
nature and quantity of additives or binders used during formulation, 
and the force of the applied pressure during compression. It, in turn, 
influences friability, disintegration time, and drug dissolution, which 
may affect drug bioavailability. Hard tablet hinders the 
disintegration process, while the soft tablet cannot resist handing 
during packing and shipping. In the current study, Out of seven, four 
brands failed to pass the optimum range of hardness; however, their 
disintegration and dissolution, as well as friability, did not affect 
accordingly. The reasons behind such a high hardness value might 
be attributed to the nature, quantity, and the force of compression 
that was utilized during the manufacturing process [26]. As a result, 
the high value in hardness making the products able to withstand 
mechanical shocks during manufacturing, handling, packaging, and 
transportation processes. This finding was in line with a previous 
study conducted on metformin tablets, which concluded that the 
crushing strength of the products was above the satisfactory limit; 
however, they showed no impact on disintegration [22]. Another 
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review article emphasized that if the tablet's hardness is too high, it 
is essential firstly to check its disintegration before rejection. It 
stated that as long as the disintegration is within acceptable limits, 
the drug will be accepted and approved [27].  
Besides, disintegration refers to the breakup of a tablet into smaller 
granules, which is an essential process for dissolution and 
absorption as well as efficacy [28]. According to USP, the 
disintegration time limit is not to be more than 30 min for uncoated 
and film-coated tablets. In the present study, all seven brands passed 
the USP-specific criteria. The discrepancies in the rate of 
disintegration of all brands might attribute, in part, to the excipients, 
the physicochemical properties of the active ingredients, the 
manufacturing procedure, and the amount used of disintegrant [6].  
Regarding the dissolution rate, it is required as a pivotal criterion for 
drug bioavailability to confirm the drug release pattern of the dosage 
form [19]. All brands in the current study released their active 
contents in a range of 90.65% to 103.05% within the allowed time as 
specified by USP. 
Compared to the general findings of this study, previous studies 
performed on levofloxacin 250 mg in Pakistan and India confirmed 
that all the brands of levofloxacin 250 mg showed satisfactory 
results regarding the physicochemical parameters tested as the USP 
specifications [1, 2]. Moreover, another comparable study conducted 
in Nigeria showed that 60% of the levofloxacin 500 mg tablet brands 
failed at least in one of the quality control parameters tests, whereas 
only 40% of the brands passed both physicochemical and 
bioequivalence tests, and they were interchangeable [29]. 
CONCLUSION  
The findings of this study are clearly demonstrated that all seven brands 
of levofloxacin 500 mg film-coated tablet, whether manufactured locally 
or in other countries, exhibited similar profiles to each other in terms of 
drug content uniformity, disintegration, dissolution, friability, and 
thickness tests, as well as uniformity test of weight variation for sex 
brands. Although four studied brands were above the optimum range of 
hardness, they showed complete disintegration and dissolution within 
the acceptable limit of USP standards. Particularly, these findings 
probably help to reinforce the feeling of shared trust between physicians 
and patients about locally and internationally manufactured medicines. 
Regular assessment of marketed drugs is required to ensure 
bioequivalence to their innovators. 
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